Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No, this is just defining how we label our revenues through self distribution. No longer any relationship with Lannett other than if there were Adderall products we sent them that haven’t yet been sold. Can’t imagine that would be the case in this time of product shortage.
Not a secret anyone actually cares about other than you.
There are no profit splits. It’s contract mfg.
I think it’s more of an 80/20 split, sometimes more favorable to generics depending how long generics have been approved.
When we launched back in 2019 I believe the total market was 1.3B. Tack on about 15-20% for total market increase since then. This amount would also include the non-generic brand & auth generics, but would think that’s maybe 15-20% of the total market max.
I love making connections like that. It’s a small world. Great to hear from you. All the best.
Last I heard API approval was the root issue. Unbelievable that DEA can’t wrap head around this. Looking forward for Elite to join Vyvanse market later this year.
Looking forward to the ramp of the first Prasco. :)
I think only way they can be valued that much is to break into international opportunities, but that can take years. Nothing has come to fruition yet via Dexcel.
That would be crazy amazing. Not sure we would get approved for that much API. I’d be more than content for half that PPS.
Huh? PR’s work isn’t as important during a cc as it is before and after. What the CEO says during a call is great, but they don’t get the word out with CC’s alone. PR or IR’s scope goes much beyond that.
To clarify, Elite isn’t the only US-based pharma Purdue is going after.
Purdue isn’t only going after Elite. They have also sued Collegium back when Elite and others submitted original ANDAs pre-insufflation study. Purdue lost this specific patent case.
https://cafc.uscourts.gov/opinions-orders/22-1482.OPINION.11-21-2023_2225603.pdf
As Enya sang, “Sell Away, Sell Away, Sell Away.” :)
I hope for longer game with buyback, uplist and then acquisition down road to execute more of pipeline. However, don’t think Nasrat will be pursuing this path.
Do you honestly think Nasrat would only pursue R/S to get to minimum price? You need a buffer. He’d also be doing this with external consulting guidance.
and along with revenue, associated COGS.
Revenue, not cash flow.
You bet. If Elite was a cash basis accounting company (mom & pop business) then revenue would be recorded as cash is received.
No, they don’t get paid upon delivery. They pay per payment terms, which could be 45-60 days.
Does it get recorded in December as revenue? Absolutely, as revenue has been earned and will be recorded regardless of when cash arrives, which hits CF statement at that time and closes out A/R on balance sheet.
Fiscal or calendar?
The likelihood of the stock appreciating with a billion shares outstanding on the OTC was slim to none. Cards were stacked against Elite. Stars are aligning and new interest is entering positions. I’ll eat my shorts. Not the first time.
I think they did many years back. All submissions were blocked by FDA for insufflation study requirement. Thx to Purdue that may have helped Elite blaze the trail despite time setback. We’ll know more this year.
Yes, expect it first half of year with filing in back half. Eager to hear about next gen product line too.
and how many others?
The word relocation used in this way means that the candidate must relocate, if needed) to be on site for first day of work. Doesn’t reference anything about moving production locations.
Depends on how much API they were allotted shifting away from being authorized generic. This is what we are blind on.
And I should care because…
Odd. I actually thought these two id’s were from the same person. Conflicting internal voices?
NASDAQ, not acquisition was the wording used. Either would be welcome news.
“This is a Carter project, I definitely want us to go to a calendar year and he is resisting. So we'll figure it out. He seems to think we'll go to NASDAQ faster, but I'm working on him. It's the first thing I asked Carter to do when he joined the company…”
Part of the immediate growth need is due to Prasco. Highly correlated issue, but I see your point.
I think he was simply stating the trajectory and that we have a whole slew of good news coming in 2024, next year and beyond. Financials, pipeline expansion and movement to submissions, facility expansion, Prasco, etc. Lots of good news coming this year setting ourselves up to get more exposure.
Come now, did you actually spend $4,000+ to read the report?
There was similar one done years ago on Abuse deterrence R&D that showed Elite made the biggest investments among all competitors and yet SequestOx is where today?
Per last cc, we are filing final needle mover in 2024, which we presume to be Concerta at this point. He mentioned also that we plan to file a 2nd ANDA that sounds like it may have a large market as well. Do we have any insights regarding this one? Don’t think it’s methotrexeate.
Purdue/Knoa will become a not for profit. I have seen larger not for profits own for profit entities, but not sure I’d expect a relationship with Elite, but never know.
I’m banking on the same.
I don’t disagree, but with the time value of money over 10 year period…
Revenue in Q3 will include launch volume shipped before Jan 1. No one knows how much this will be. Perhaps it will be small and we’re overshooting. We’ll know soon enough in a couple week’s time and hoping to get a Prasco glimpse for going forward.
What Purdue did to push oxy is unbelievable with a total lack of integrity. There are many who need this drug and I think Elite will put the right processes and controls in place to market and distribute responsibly.
How could it be flat when you include Prasco launch quantity?